| Patents for A61P 25 - Drugs for disorders of the nervous system (183,225) |
|---|
| 05/08/2002 | EP1202966A1 Piperidine alcohols |
| 05/08/2002 | EP1202965A1 Indole derivatives, processes for their preparation, pharmaceutical compositions containing them and their medicinal application |
| 05/08/2002 | EP1202964A1 Condensed indoline derivatives and their use as 5ht, in particular 5ht2c, receptor ligands |
| 05/08/2002 | EP1202953A2 Substituted 2-dialkylaminoalkylbiphenyl derivatives |
| 05/08/2002 | EP1202743A2 Fish serine proteinases and their pharmaceutical and cosmetic use |
| 05/08/2002 | EP1202741A1 Neurotropic virus transport |
| 05/08/2002 | EP1202738A1 Dihydropyrazine derivatives as npy antagonists |
| 05/08/2002 | EP1202733A1 3(5)-amino-pyrazole derivatives, process for their preparation and their use as antitumor agents |
| 05/08/2002 | EP1202732A2 Method for treating chronic pain using mek inhibitors |
| 05/08/2002 | EP1202731A2 Method for treating chronic pain using mek inhibitors |
| 05/08/2002 | EP1202730A2 Use of ep4 receptor ligands in the treatment of neuropathic pain and colon cancer |
| 05/08/2002 | EP1202727A1 Use of agonists of gabab receptors and pharmaceutically acceptable derivatives thereof, in the therapy of maintaining nicotine abstinence in nicotine-dependent patients |
| 05/08/2002 | EP1202726A2 Method for treating chronic pain using mek inhibitors |
| 05/08/2002 | EP1202724A2 Method for treating chronic pain using mek inhibitors |
| 05/08/2002 | EP1202722A1 Uses compositions for treating or preventing sleep disturbances using very low doses of cyclobenzaprine |
| 05/08/2002 | EP1202721A1 Cyclobenzaprine for treating generalized anxiety disorder and compositions thereof |
| 05/08/2002 | EP1202720A1 Use of gaba agonists for treatment of spastic disorders, convulsions, and epilepsy |
| 05/08/2002 | EP1202717A2 Naaladase inhibitors in anxiety and memory disorders |
| 05/08/2002 | EP1202628A1 Novel hypoxanthine and thiohypoxanthine compounds |
| 05/08/2002 | EP1087966B1 Chemical synthesis of morpholine derivatives |
| 05/08/2002 | EP1007040B1 Use of phanquinone for the treatment of alzheimer's disease |
| 05/08/2002 | EP0923585B1 Phosphinate based inhibitors of matrix metalloproteases |
| 05/08/2002 | EP0914332B1 Isoquinolines useful as analgesics |
| 05/08/2002 | EP0790994B1 Heterocycle substituted propenoic acid derivatives as nmda antagonists |
| 05/08/2002 | DE10054482A1 Heteroarylacryloylaminoalkyl-substituierte Benzolsulfonamidderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate Heteroarylacryloylaminoalkyl-substituted benzenesulfonamide derivatives, their preparation, their use and pharmaceutical compositions containing them |
| 05/08/2002 | DE10054481A1 Acylaminoalkyl-substituierte Benzolsulfonamidderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate Acylaminoalkyl-substituted benzenesulfonamide derivatives, their preparation, their use and pharmaceutical compositions containing them |
| 05/08/2002 | DE10053813A1 Neue Verwendung von Sulfonamiden New use of sulfonamides |
| 05/08/2002 | CN1348497A 载体 Carrier |
| 05/08/2002 | CN1348454A Tetracyclic azepinoindole compounds as 5-HT receptor ligands |
| 05/08/2002 | CN1348451A Azaindole derivatives for the treatment of depression |
| 05/08/2002 | CN1348450A Tetrahydroisoquinolinyl-indole derivatives for the treatment of depression |
| 05/08/2002 | CN1348449A Heteroaryl diazacycloalkanes, their preparation and use |
| 05/08/2002 | CN1348447A 4,5-diaryl-3(i(2H))-furanone derivatives as cyclooxygenase-2 inhibitors |
| 05/08/2002 | CN1348446A Heterocyclic carboxamide-containing thiourea inhibitors of herpes viruses containing phenylenediamine group |
| 05/08/2002 | CN1348444A 丝氨酸蛋白酶抑制剂 Serine protease inhibitors |
| 05/08/2002 | CN1348442A Novel sulfonamide compounds and uses thereof |
| 05/08/2002 | CN1348439A New compounds, their preparation and use |
| 05/08/2002 | CN1348379A Compositions containing rubidium and in particular rubidium chloride as an antimanic agent and stabilizer for mood swings |
| 05/08/2002 | CN1348375A Pharmaceutical compositions comprising cyclic glycerophosphates and analogs thereof for promoting neural cell differentiation |
| 05/08/2002 | CN1348371A Use of saredutant and the pharmaceutically acceptable salts thereof to produce medicaments used to treat or prevent mood disorders, adjustment disorders or mixed anxiety-depression disorders |
| 05/08/2002 | CN1348370A Cyclic protein tyrosine kinase inhibitors |
| 05/08/2002 | CN1348363A Novel pharmaceutical salt form |
| 05/08/2002 | CN1348359A Composition for medicated chewing gums process for manufacturing the same and tablets so obtained |
| 05/08/2002 | CN1347874A Application of small dosage of aminoguanidine in anti-senility and preventing and treating senile diseases |
| 05/08/2002 | CN1347868A Saffron extract with the effect of improving cerebral function |
| 05/08/2002 | CN1347701A Seahorse powder capsule |
| 05/08/2002 | CN1347699A Use of stilbene glycoside in treating dementia |
| 05/08/2002 | CN1084329C Benzyl piepridine derivative |
| 05/08/2002 | CN1084186C Liposome composition containing selegilin |
| 05/07/2002 | US6384281 3-bicycloaryl-2-aminomethyl bicycloalkanes as serotonine reuptake inhibitors |
| 05/07/2002 | US6384252 Fatty acids or derivatives; mammalian mammary glands secretion; stress, anxiety and aggression reduction |
| 05/07/2002 | US6384226 Process for the preparation of 2-phenyl-imidazo [1, 2-a] pyridine-3-acetamides |
| 05/07/2002 | US6384225 Intermediates in the preparation of substituted chroman derivatives |
| 05/07/2002 | US6384222 N-benzenesulfonyl-L-proline compounds, preparation method and method for using the compounds in therapy |
| 05/07/2002 | US6384218 Prepared by reacting amino acid, oligo- or polypeptide or polyamino acid with trialdehyde; molecular recognition agent for use in neurotransmission studies |
| 05/07/2002 | US6384083 Controlling viruses of bornaviridae family by administering adamantane amines to human and animals at therapeutically effective dosage by means selected from oral, parenteral, intramuscular, subcutaneous, intradermal and topical |
| 05/07/2002 | US6384077 Highly purified EPA for treatment of schizophrenia and related disorders |
| 05/07/2002 | US6384055 Analgesics |
| 05/07/2002 | US6384037 R-hydroxynefazodone |
| 05/07/2002 | US6384034 Method of treating migraines and pharmaceutical compositions |
| 05/07/2002 | US6384022 Enzyme inhibitors |
| 05/07/2002 | US6383790 Pyrazolo(3,4-d)pyrimidine based compound; anticarcinogenic agents; antitumor agents |
| 05/07/2002 | US6383785 Self-enhancing, pharmacologically controllable expression systems |
| 05/07/2002 | US6383780 2786, a novel human aminopeptidase |
| 05/07/2002 | US6383526 Extraction in alcohol of valerenic acid while minimizing valepotriates and valepotriate degradation products; used as sedative, muscle relaxant, or anxiolytic agent |
| 05/07/2002 | US6383511 Local prevention or amelioration of pain from surgically closed wounds |
| 05/07/2002 | US6383509 Continuous in vivo release of a neurotoxin over a treatment period extending from one month to five years; neurotoxin, especially botulinum toxin or clostridial neurotoxin, within a polymeric matrix |
| 05/07/2002 | CA2216535C Protein kinase c inhibitors |
| 05/07/2002 | CA2214884C Poly(hydroxy acid)/polymer conjugates for skin applications |
| 05/07/2002 | CA2145000C Compounds which are selective antagonists of the human nk3 receptor and their use as medicinal products and diagnostic tools |
| 05/02/2002 | WO2002035235A2 Net as regulator of angiogenic expression |
| 05/02/2002 | WO2002035231A1 Screening method using a g coupled receptor associated with a specific g protein |
| 05/02/2002 | WO2002034940A2 Methods for screening compounds that modulate lipid metabolism |
| 05/02/2002 | WO2002034920A2 Regulation of human ceruloplasmin-like protein |
| 05/02/2002 | WO2002034915A2 Preferred segments of neural thread protein and methods of using the same |
| 05/02/2002 | WO2002034889A2 Therapeutic uses for mesenchymal stromal cells |
| 05/02/2002 | WO2002034783A2 Transmembrane proteins |
| 05/02/2002 | WO2002034781A1 Human g-protein coupled diadenosine tetraphosphate receptor (ap4ar) |
| 05/02/2002 | WO2002034777A1 Fusion proteins as immunization treatments of alzheimer's disease |
| 05/02/2002 | WO2002034761A1 Pyranoside derivatives |
| 05/02/2002 | WO2002034754A2 Benzoxazinone derivatives, their preparation and use |
| 05/02/2002 | WO2002034753A2 Spiro-pyrimidine-2,4,6-trione metalloproteinase inhibitors |
| 05/02/2002 | WO2002034747A1 Novel 7-azaindoles, use thereof as phosphodiesterase 4 inhibitors and method for producing the same |
| 05/02/2002 | WO2002034741A2 A NOVEL CRYSTALLINE FORM OF 6-HYDROXY-3-(4-[2-(PIPERIDIN-1-YL)ETHOXY]PHENOXY)-2-(4-METHOXYPHENYL)BENZO[b]THIOPHENE HYDROCHLORIDE |
| 05/02/2002 | WO2002034726A2 Pyrimidine-2,4,6-trione metalloproteinase inhibitors |
| 05/02/2002 | WO2002034721A1 Acylsemicarbazides and their use as cyclin dependent kinase (cdk) inhibitors |
| 05/02/2002 | WO2002034718A1 Amide derivatives as nmda receptor antagonists |
| 05/02/2002 | WO2002034716A2 Pyrrolidine modulators of ccr5 chemokine receptor activity |
| 05/02/2002 | WO2002034699A2 Mammalian metabolites of a tachykinin receptor antagonist |
| 05/02/2002 | WO2002034278A1 Total glycosides of dangshen and their use as an aid for memory acquisition, retention and/or retrieval |
| 05/02/2002 | WO2002034272A2 Methods of improving central nervous system functioning |
| 05/02/2002 | WO2002034267A1 Combination of a transdermal therapeutic system and an oral and/or parenteral preparation containing dopamine agonists for the treatment of dopaminergic disease states |
| 05/02/2002 | WO2002034257A1 Agents for recoverying from or preventing fatigue in the central nerve system and foods for recoverying from or preventing fatigue |
| 05/02/2002 | WO2002034252A1 Drug composition comprising dipeptydyl aldehyde derivative |
| 05/02/2002 | WO2002034249A1 Treatment of pcp addiction and pcp addiction-related behavior |
| 05/02/2002 | WO2002034243A2 Method for the treatment of neurological and neuropsychological disorders |
| 05/02/2002 | WO2002034242A2 Method for the treatment of neurological and neuropsychological disorders |
| 05/02/2002 | WO2002034202A2 Multi-component antioxidant compounds, pharmaceutical compositions containing same and their use for reducing or preventing oxidative stress |
| 05/02/2002 | WO2002019812A3 Mutant non-human mammal for expressing the alpha6 acetylcholine nicotinic receptor subunit and use for screening substances capable of interacting with said receptor |
| 05/02/2002 | WO2002007726A8 Treatment of movement disorders |